Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) dropped 3.5% during trading on Tuesday . The company traded as low as $7.01 and last traded at $7.10. Approximately 3,500 shares changed hands during mid-day trading, an increase of 29% from the average daily volume of 2,714 shares. The stock had previously closed at $7.36.
Clinuvel Pharmaceuticals Trading Down 0.7%
The stock has a fifty day moving average price of $6.71 and a two-hundred day moving average price of $7.39.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
